Moderna Inc (NASDAQ: MRNA) shares came under significant selling pressure Thursday afternoon following an adverse patent ruling, and the stock is adding to the losses in Friday’s session.
Moderna Loses Patent Challenge: In an ongoing legal dispute, the Patent Trial and Appeal Board ruled against Moderna’s challenge to the patentability of Arbutus Biopharma Corp’s (NASDAQ: ABUS) ABUS’069 patent.
The ‘069 patent covers liquid nanoparticle formulations, or LNPs, meant for nucleic acid delivery, which is used by Moderna in its vaccine candidates.
The patent describes the composition of nucleic acid-lipid particles and the ranges in which the different lipid particle components can be combined for effective delivery of nucleic acid sequence payload.
Moderna holds four non-exclusive viral vaccine sublicenses of Arbutus-issued LNP delivery technology. Each one allows for the use of pre-April 15, 2010 LNP patent families and is limited to a specific viral target, Chardan analyst Keay Nakae said in